Current and future treatment of amyloid neuropathies.
Le Kremlin-Bicêtre, France. In Expert Rev Neurother, 21 Dec 2014
Poor prognosis is related to progressive neuropathy and associated, although often underdiagnosed, cardiac involvement in specific transthyretin (TTR) gene mutations.
Pathophysiology and treatment of cardiac amyloidosis.
Rochester, United States. In Nat Rev Cardiol, 14 Nov 2014
Mass spectroscopy can be used to determine the protein subunit and classify the disease as immunoglobulin light-chain amyloidosis or transthyretin-related amyloidosis associated with mutant or wild-type TTR (formerly known as familial amyloid cardiomyopathy and senile cardiac amyloidosis, respectively).
Amyloid fibrils nucleated and organized by DNA origami constructions.
New York City, United States. In Nat Nanotechnol, Jul 2014
The fibrils are built by modifying the synthetic peptide fragment corresponding to residues 105-115 of the amyloidogenic protein transthyretin and a DNA origami construct is used to form 20-helix DNA nanotubes with sufficient space for the fibrils inside.
Recent advances in transthyretin amyloidosis therapy.
Kumamoto, Japan. In Transl Neurodegener, Dec 2013
Mutant (MT) forms of transthyretin (TTR) cause the most common type of autosomal-dominant hereditary systemic amyloidosis-familial amyloidotic polyneuropathy (FAP).
Transport of thyroid hormone in brain.
Berlin, Germany. In Front Endocrinol (lausanne), Dec 2013
One of these proteins, transthyretin is also present in the cerebrospinal fluid (CSF) after being secreted by the choroid plexus.